The global drug and gene delivery devices market is anticipated to reach nearly USD 787 billion by 2025. Efforts towards creating dosage forms that maximize the bioavailability of a drug at the target site, while enhancing patient convenience may drive the global market over the forecast period (2016 to 2025). The advent of new drug delivery systems, for example, subdermal implants-available in various forms such as patches and rings, is expected to support market growth. Advancements in drug delivery systems can be credited to the frequently changing preferences of healthcare professionals and of patients.
The global industry for drug and gene delivery devices is categorized on the basis of routes of administration, vectors, methods, and regions. Based on the routes of administration, the industry is divided into oral, transdermal, inhalation, injectable, nasal, topical, and ocular. The oral segment dominated the overall market and accounted for the highest share in 2015. Low production costs and ease of use are chief factors that fuel this segment. The injectable segment can witness robust growth because of the introduction of sophisticated injecting devices that facilitate self-injection.
On the basis of methods, the overall industry is categorized into ex vivo and in situ. At present, most of the approved drugs act as per the “in situ” methods. Hence, the “in situ” segment currently dominates the industry. It holds highest shares among the other moderately performing segments. In situ methods are easy to use & apply which is why their surging popularity could make this segment a rapidly expanding one. However, low efficiency of the transduction methods could hamper its progress over the forecast period.
In-depth research report on global drug and gene delivery devices market - http://www.grandviewresearch.com/industry-analysis/drug-gene-delivery-devices-market
According to vectors, the market is bifurcated into viral and non-viral segments. With four approved drugs, viral vectors dominate the worldwide drug and gene delivery devices market at present. Almost up to 60% of the current medical trials on gene treatments for transfection are based on viral vectors. Hence, the segment may continue dominating the industry over the next nine years. Viral vectors help facilitate complex methods involved in transfection, such as magnetofection, gene gun, hydrodynamic, and ultrasound. Furthermore, viral vectors exhibit higher success rates in gene transfers unlike other similar methods.
Geographically, the worldwide drug and gene delivery devices industry is divided into Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa (MEA). North America dominated the overall industry in 2015. The region may continue leading the market during the forecast period on account of high healthcare expenditure and well-developed healthcare infrastructure. Asia-Pacific can register the highest growth rate over the next couple of years. Regional drivers are surging disposable incomes, rapid economic development, and widespread acceptance of highly developed delivery systems.
Key players operating in the global drug and gene delivery devices market are Shenzhen SiBiono GeneTech Co. Ltd.; Epeius Biotechnologies Corp.; Uniqure N. V.; Human Stem Cells Institute OJSC; and Shanghai Sunway Biotech Co. Ltd. These companies lay great emphasis on product development so as to capture higher shares in the global market.